IR@PKUHSC  > 北京大学临床肿瘤学院  > 消化科
学科主题临床医学
Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine
Zhang Tong1; He Wen-ting2; Zi Ming-jie3; Song Gang4; Yi Dan-hui5; Yang Yu-fei1
通讯作者Yang Yu-fei(1)
关键词cohort study metastatic colorectal cancer integrative medicine
刊名CHINESE JOURNAL OF INTEGRATIVE MEDICINE
2018-08-01
DOI10.1007/s11655-018-2980-0
24期:8页:573-578
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Integrative & Complementary Medicine
研究领域[WOS]Integrative & Complementary Medicine
英文摘要

Objective: To investigate the efficacy of integrated Chinese and Western medicine (IM) in the treatment of metastatic colorectal cancer (mCRC) in a cohort study. Methods: The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone. The study design was adopted with "continuous administration of Chinese medicine for >= 3 months" as the exposure factor. Patients who met this exposure factor were assigned to the IM cohort (Group A, 110 patients). Patients who did not meet this exposure factor were assigned to the Western medicine cohort (Group B, 225 patients). The overall survival (OS), progression-free survival (PFS), and 1st year, 2nd year, and 3rd year survival in the two cohorts were compared. Results: The median OS in Group A and B were 18 months [95% confidence interval (CI) 15-21] and 16 months (95% CI 14-18), respectively, and the median PFS in Group A and B were 6 months (95% CI 4-7) and 5 months (95% CI 4-6), respectively. No statistically significant differences were observed between the groups (P=0.186, P=0.223). Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups: female patients, patients with lesions in the right half of the colon, and those who received first-line treatment (P<0.05). In the subgroup of elderly patients (age>65 years), the OS in Group A was longer than that in Group B (P<0.05). Conclusion: IM could prolong the survival of patients with mCRC.

语种英语
WOS记录号WOS:000443011600003
通讯作者邮箱yyf93@vip.sina.com
第一作者单位China Acad Chinese Med Sci, Xiyuan Hosp, Dept Oncol, Beijing 100091, Peoples R China
通讯作者单位China Acad Chinese Med Sci, Xiyuan Hosp, Dept Oncol, Beijing 100091, Peoples R China
ISSN1672-0415
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142901
专题北京大学临床肿瘤学院_消化科
北京大学第一临床医学院_泌尿外科
作者单位1.China Acad Chinese Med Sci, Xiyuan Hosp, Dept Oncol, Beijing 100091, Peoples R China;
2.Xinjiang Med Univ, Tradit Chinese Med Hosp, Dept Oncol 2, Urumqi 830001, Peoples R China;
3.China Acad Chinese Medicial Sci, Xiyuan Hosp, Eth Comm, Beijing, Peoples R China;
4.Beijing Canc Hosp, Dept Digest Oncol, Beijing 100036, Peoples R China;
5.Renmin Univ China, Sch Stat, Beijing 100872, Peoples R China
推荐引用方式
GB/T 7714
Zhang Tong,He Wen-ting,Zi Ming-jie,et al. Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine[J]. CHINESE JOURNAL OF INTEGRATIVE MEDICINE,2018,24(8):573-578.
APA Zhang Tong,He Wen-ting,Zi Ming-jie,Song Gang,Yi Dan-hui,&Yang Yu-fei.(2018).Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine.CHINESE JOURNAL OF INTEGRATIVE MEDICINE,24(8),573-578.
MLA Zhang Tong,et al."Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine".CHINESE JOURNAL OF INTEGRATIVE MEDICINE 24.8(2018):573-578.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang Tong]的文章
[He Wen-ting]的文章
[Zi Ming-jie]的文章
百度学术
百度学术中相似的文章
[Zhang Tong]的文章
[He Wen-ting]的文章
[Zi Ming-jie]的文章
必应学术
必应学术中相似的文章
[Zhang Tong]的文章
[He Wen-ting]的文章
[Zi Ming-jie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。